Advancing Immunotherapy for Colon Cancer In a significant milestone for oncology research, Akeso, Inc. has officially announced that the first patient has been dosed in a global Phase III clinical trial evaluating cadonilimab. This study focuses on the perioperative treatment of patients with locally advanced colon cancer. Understanding Cadonilimab Cadonilimab is a novel, potentially first-in-class…